Providers under pressure:  Behind the numbers 2024​

The cost of treating patients is expected to rise 7% next year as providers seek rate increases to deal with higher expenses and prescription drug spending accelerates, according to PwC’s new report, Behind the Numbers 2024. To estimate the cost to treat patients for the coming year, PwC’s Health Research Institute surveyed and spoke with US health plans covering 100 million employer-sponsored large and small group members and 10 million Affordable Care Act (ACA) marketplace members. Here are some highlights of the report for the two major medical cost inflators and two major medical cost deflators cited by health plans:  

Advertisement

Inflators: Inflationary impacts from healthcare providers and pharmaceutical costs  

All health plans ranked inflation’s impact on healthcare providers among the top three inflators for 2024. In a persisting high inflationary environment, hospitals and providers will often be pushed to seek significant rate increases from payers. The ability of health plans to manage price increases during contract renewals will be a key factor in determining the impact of inflation in the coming years.​ Recent years’ clinical workforce shortages further compound inflationary pressure. Assuming the persistence of the staff shortages in 2024, hospitals will continue to be financially challenged and seek higher reimbursement from payers. 

Physician consolidation can further amplify the effect of the workforce shortage.​ Providers should be proactive in attracting healthcare talent and doing more with less while also quickly leveraging technology such as AI to ease the workforce strain. ​  

​Plans are also experiencing inflationary pressure from rising median prices of new drugs as well as increasing prices of existing drugs. Combined with the accelerated approvals of new cell and gene therapies, pharmacy trends are not expected to slow down in 2024.​The inflationary impact on pharmaceutical manufacturers is expected to be in the high single or double digits from 2023-24. ​ 

Deflators: ​Biosimilars coming to market and shifts in care  

The prices of biosimilars are, on average more than 50% lower than the reference products for which they can substitute. The adoption of biosimilars to specialty drugs has substantial potential to manage the rising drug cost. The industry will keep watching for any future regulatory/legislative actions that impact the biosimilar market, as many players appear to remain committed to the near and long-term growth of the biosimilar market.  

​The pandemic also rapidly shifted the site of care from more expensive inpatient hospital settings to less expensive outpatient or emergency rooms. ​​Health plans reported a decrease in inpatient utilization as well as a shift toward outpatient settings, allowing a two-pronged benefit to contain costs.  ​Providers have an important role to play. They can work with plans to establish ownership models that share financial gains and incentivize physicians to accelerate the shift to outpatient care. This can help ease the pressure on inpatient settings, where capacity has been the slowest to recover across the country, driven by the lack of skilled clinical labor.  

To read the full report and how providers can prepare, go to Behind the Numbers 2024. 

Contact: 

Thom Bales, Principal, PwC US 

thom.bales@pwc.com 

Derek Skoog, Principal, PwC US 

Derek.g.skoog@pwc.com 

Advertisement

Next Up in Financial Management

Advertisement

Comments are closed.